LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Su Jin Lee; Sun Ju Byeon; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim; Kyoung Mee Kim; Seung Tae Kim

doi:10.1097/CJI.0000000000000283

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Su Jin Lee, Sun Ju Byeon, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim, Kyoung Mee Kim, Seung Tae Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

We performed a prospective immunohistochemical analysis of lymphocyte activation gene 3 (LAG3) for 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016. Most patients (428/430, 99.5%) were evaluable for LAG3 expression by immunohistochemistry. In total, 18.5% (79/428) of the evaluated cancers expressed LAG3, including pancreatic cancer (33.3%, 2/6), gastric cancer (24.7%, 21/85), colorectal cancer (23.6%, 48/203), melanoma (12.5%, 1/8), genitourinary cancer (9.5%, 4/46), biliary tract cancer (6.3%, 1/16), and sarcoma (5.4%, 2/37), but not miscellaneous (0.0%, 0/14) or hepatocellular (0.0%, 0/15) cancer. Among 149 metastatic colorectal cancer patients, there was no statistically significant difference in sex, age, primary tumor site, pathologic differentiation, KRAS and NRAS status, BRAF status, and microsatellite instability according to LAG3 status (expressed vs. nonexpressed). Among 53 metastatic gastric cancer patients, LAG3 was only significantly associated with Epstein Barr virus status (P=0.042). Our results add to the emerging literature on LAG3 expression in various cancer types and support the need for extended clinical exploration of this target for immunotherapy.

Original language	English
Pages (from-to)	279-283
Number of pages	5
Journal	Journal of Immunotherapy
Volume	42
Issue number	8
DOIs	https://doi.org/10.1097/CJI.0000000000000283
State	Published - 1 Oct 2019

Bibliographical note

Funding Information:
grant from the 20 by 20 Project of Samsung Medical Center (GF01140111).

Funding Information:
Supported by funding from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a

Funding Information:
Supported by funding from the Korean Health Technology R and D Project, Ministry of Health &Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). All authors have declared that there are no financial conflicts of interest with regard to this work.

Publisher Copyright:
© 2019 Lippincott Williams and Wilkins. All rights reserved.

Keywords

biomarker
immunohistochemistry
immunotherapy
LAG3
solid cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/CJI.0000000000000283

Cite this

@article{49c5477bb4cf43c498106c7e2d514638,

title = "LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target",

abstract = "We performed a prospective immunohistochemical analysis of lymphocyte activation gene 3 (LAG3) for 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016. Most patients (428/430, 99.5%) were evaluable for LAG3 expression by immunohistochemistry. In total, 18.5% (79/428) of the evaluated cancers expressed LAG3, including pancreatic cancer (33.3%, 2/6), gastric cancer (24.7%, 21/85), colorectal cancer (23.6%, 48/203), melanoma (12.5%, 1/8), genitourinary cancer (9.5%, 4/46), biliary tract cancer (6.3%, 1/16), and sarcoma (5.4%, 2/37), but not miscellaneous (0.0%, 0/14) or hepatocellular (0.0%, 0/15) cancer. Among 149 metastatic colorectal cancer patients, there was no statistically significant difference in sex, age, primary tumor site, pathologic differentiation, KRAS and NRAS status, BRAF status, and microsatellite instability according to LAG3 status (expressed vs. nonexpressed). Among 53 metastatic gastric cancer patients, LAG3 was only significantly associated with Epstein Barr virus status (P=0.042). Our results add to the emerging literature on LAG3 expression in various cancer types and support the need for extended clinical exploration of this target for immunotherapy.",

keywords = "biomarker, immunohistochemistry, immunotherapy, LAG3, solid cancer",

author = "Lee, {Su Jin} and Byeon, {Sun Ju} and Jeeyun Lee and Park, {Se Hoon} and Park, {Joon Oh} and Park, {Young Suk} and Kang, {Won Ki} and Lim, {Ho Yeong} and Kim, {Kyoung Mee} and Kim, {Seung Tae}",

note = "Funding Information: grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). Funding Information: Supported by funding from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a Funding Information: Supported by funding from the Korean Health Technology R and D Project, Ministry of Health &Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). All authors have declared that there are no financial conflicts of interest with regard to this work. Publisher Copyright: {\textcopyright} 2019 Lippincott Williams and Wilkins. All rights reserved.",

year = "2019",

month = oct,

day = "1",

doi = "10.1097/CJI.0000000000000283",

language = "English",

volume = "42",

pages = "279--283",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "8",

}

TY - JOUR

T1 - LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

AU - Lee, Su Jin

AU - Byeon, Sun Ju

AU - Lee, Jeeyun

AU - Park, Se Hoon

AU - Park, Joon Oh

AU - Park, Young Suk

AU - Kang, Won Ki

AU - Lim, Ho Yeong

AU - Kim, Kyoung Mee

AU - Kim, Seung Tae

N1 - Funding Information: grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). Funding Information: Supported by funding from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a Funding Information: Supported by funding from the Korean Health Technology R and D Project, Ministry of Health &Welfare, Republic of Korea (HI16C1990, HI14C2188). Support was also provided by a grant from the 20 by 20 Project of Samsung Medical Center (GF01140111). All authors have declared that there are no financial conflicts of interest with regard to this work. Publisher Copyright: © 2019 Lippincott Williams and Wilkins. All rights reserved.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - We performed a prospective immunohistochemical analysis of lymphocyte activation gene 3 (LAG3) for 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016. Most patients (428/430, 99.5%) were evaluable for LAG3 expression by immunohistochemistry. In total, 18.5% (79/428) of the evaluated cancers expressed LAG3, including pancreatic cancer (33.3%, 2/6), gastric cancer (24.7%, 21/85), colorectal cancer (23.6%, 48/203), melanoma (12.5%, 1/8), genitourinary cancer (9.5%, 4/46), biliary tract cancer (6.3%, 1/16), and sarcoma (5.4%, 2/37), but not miscellaneous (0.0%, 0/14) or hepatocellular (0.0%, 0/15) cancer. Among 149 metastatic colorectal cancer patients, there was no statistically significant difference in sex, age, primary tumor site, pathologic differentiation, KRAS and NRAS status, BRAF status, and microsatellite instability according to LAG3 status (expressed vs. nonexpressed). Among 53 metastatic gastric cancer patients, LAG3 was only significantly associated with Epstein Barr virus status (P=0.042). Our results add to the emerging literature on LAG3 expression in various cancer types and support the need for extended clinical exploration of this target for immunotherapy.

AB - We performed a prospective immunohistochemical analysis of lymphocyte activation gene 3 (LAG3) for 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016. Most patients (428/430, 99.5%) were evaluable for LAG3 expression by immunohistochemistry. In total, 18.5% (79/428) of the evaluated cancers expressed LAG3, including pancreatic cancer (33.3%, 2/6), gastric cancer (24.7%, 21/85), colorectal cancer (23.6%, 48/203), melanoma (12.5%, 1/8), genitourinary cancer (9.5%, 4/46), biliary tract cancer (6.3%, 1/16), and sarcoma (5.4%, 2/37), but not miscellaneous (0.0%, 0/14) or hepatocellular (0.0%, 0/15) cancer. Among 149 metastatic colorectal cancer patients, there was no statistically significant difference in sex, age, primary tumor site, pathologic differentiation, KRAS and NRAS status, BRAF status, and microsatellite instability according to LAG3 status (expressed vs. nonexpressed). Among 53 metastatic gastric cancer patients, LAG3 was only significantly associated with Epstein Barr virus status (P=0.042). Our results add to the emerging literature on LAG3 expression in various cancer types and support the need for extended clinical exploration of this target for immunotherapy.

KW - biomarker

KW - immunohistochemistry

KW - immunotherapy

KW - LAG3

KW - solid cancer

UR - http://www.scopus.com/inward/record.url?scp=85071787714&partnerID=8YFLogxK

U2 - 10.1097/CJI.0000000000000283

DO - 10.1097/CJI.0000000000000283

M3 - Article

C2 - 31219974

AN - SCOPUS:85071787714

SN - 1524-9557

VL - 42

SP - 279

EP - 283

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

IS - 8

ER -

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this